✨ Free AI Report
Valneva SE: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Valneva SE
Company Research

Valneva SE: Business Overview, Financials & Competitive Analysis

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. The company commercializes three approved travel vaccines (IXIA...

Analyst-debate audio for Valneva SE

AskCyborg analysts argue the bull and bear cases for Valneva SE across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Specialty vaccine developer with meaningful near-term revenue growth potential and downstream optionality from late-stage Lyme...

Read the full analyst-debate transcript →
Industry Specialty Vaccines / Infectious Disease Therapeutics
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Valneva SE Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Valneva SE Overview

Pro stress-test →

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. The company commercializes three approved travel vaccines (IXIARO for Japanese encephalitis, DUKORAL for cholera/traveler's diarrhea, and IXCHIQ for chikungunya) while advancing a robust pipeline of vaccine candidates including VLA15 for Lyme disease, programs for Zika, shigellosis, and other infectious diseases.

Strategic Profile

Pro stress-test →

Valneva operates multi-site manufacturing infrastructure across Scotland, Sweden, and Austria, positioning it to serve global markets across North America and Europe. The company is transitioning from travel vaccine focus to address significant unmet medical needs in endemic infectious diseases, with recent positive clinical data supporting advancement of pipeline programs toward market expansion and diversification.

Competitive Landscape

Pro stress-test →

Valneva competes against larger established vaccine manufacturers (Merck, GSK, Sanofi, Pfizer) in travel and infectious disease vaccines while competing with emerging biotech in niche areas like Lyme disease. The company's differentiation lies in proprietary vaccine platforms, manufacturing capabilities, and focus on unmet medical needs in neglected infectious disease areas.

Industry Context

Valneva SE operates in Specialty Vaccines / Infectious Disease Therapeutics.

Key facts

Founded: 1998 · Headquarters: Saint-Herblain, France · Employees: 676 · Revenue: $169.6M · Market cap: $0.7B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Valneva SE.

  • 2024 revenue was $169.58 million, an increase of 10.32% compared to the previous year's $153.71 million
  • Analyst consensus rates the stock as "Strong Buy" with a 12-month price target of $15.75, implying 56.87% upside
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Announced positive antibody persistence and safety data for Lyme disease vaccine VLA15 from Phase 2 trial
  • December 2025Reported positive Phase 1 results for Zika vaccine VLA1601 with positive immunogenicity data
  • +2 moreTrack every material event for Valneva SE as it happens. Explore monitoring →
Get alerted when Valneva SE has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GARDASIL/SILGARDInfectious disease vaccines→TYVERIXTravel and infectious disease vaccines→PENTACELVaccine platform and travel vaccines→Lyme Disease Vaccine ProgramsEmerging vaccine candidates→

Compare Valneva SE with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Valneva SE operates in Specialty Vaccines / Infectious Disease Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Vaccines / Infectious Disease Therapeutics research →
NEW · MCP server

Ask your AI assistant about Valneva SE

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Valneva SE and its top competitor on Cyborg Score”
“What did Valneva SE do this quarter?”
“Is Valneva SE a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Valneva SE do?+
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. The company commercializes three approved travel vaccines (IXIA...
What is Valneva SE's Cyborg Score?+
Valneva SE has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Valneva SE's main competitors?+
Named competitors include GARDASIL/SILGARD, TYVERIX, PENTACEL, Lyme Disease Vaccine Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Valneva SE research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Valneva SE research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Valneva SE over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Vaccines research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Valneva SE